Navigation Links
Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
Date:12/3/2007

STUDIO CITY, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced its presence at the XIII World Congress on Cardiac Pacing and Electrophysiology to be held December 2-6, 2007 in Rome, Italy. At the Congress, Dr. Muricio Arruda, who has been testing Signalife's wireless Fidelity 400 Intracardiac Monitor at the Electrophysiology Laboratories of the Cleveland Clinic Heart Center, will present a prototoype of the Fidelity 400 Intracardiac Monitor to selected participants. The Signalife Fidelity 400 Intracardiac Monitor applies Signalife's award-winning proprietary physiological signal acquisition and amplification technology to read intracardiac signals procured from intracardiac catheter products. An intracardiac catheter is a flexible tube that is inserted through a vein in the leg and fed into the heart. The catheter is equipped with electrodes which allows the signal to be recorded within the heart, and the catheter data is transmitted to a monitor, which allows the physician to evaluate cardiac function, including arrhythmia, or irregular heartbeat. These readings are beneficial in that they measure signals directly from the heart, as opposed to signals read from the surface of the body as is typical in the ordinary application of heart monitors.

The mission of the World Congress of Cardiac Pacing and Electrophysiology is to provide an education forum, underlining evidence-based clinical practices in the field of arrhythmology for clinical cardiologists and electrophysiologists. The Congress will also highlight the latest and most advanced topics in invasive electrophysiology and cardiac pacing, giving leading electrophysiologists the opportunity to demonstrate and discuss new diagnostic and therapeutic strategies.

Dr. Arruda, a faculty member of the XIII World Congress, stated: "I am very happy and impressed with the progress made by the Signalife research & development team on the Fidelity 400 multi- channel, wireless ECG/IC system from the initial results presented at the 2006 Heart and Rhythm Society Conference. The main objective and benefit of the novel system is to offer a technology that overcomes problems presently associated with recordings of surface ECG and intracardiac signals during electrophysiological studies".

Dr. Budimir Drakulic, Signalife's Chief Technology Officer, stated: "We have applied Signalife's patented signal processing technology to intracardiac signals with the same success realized with ambulatory ECG recordings and are looking forward to further development of this technology. We intend to file this one-of-a-kind intra-cardiac monitor for FDA approval shortly."

Dr Lowell Harmison, Signalife's President, states that "this technology application will allow us to get new data concerning a host of electrophysiological changes in the heart that were not impossible to be obtained before. Our electrocardiography technology is opening new opportunities for medical research and clinical findings based on getting a more accurate and definitive ECG signal in the catheterization lab and surgery as well as under conditions of stress and a spectrum of ambulatory conditions. It is becoming a powerful new tool for cardiac monitoring and for improved cardiac care."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Provides Corporate Update
2. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Signalife Receives Another $3.3 Million Sales Orders
6. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
7. Signalife Continues to Procure Purchase Orders, Revenues
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. U.S. Patent 7,299,083 Awarded to Signalife
10. Medpace Strengthens Presence in Central Europe
11. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):